Skip to main content
. 2021 May 22;22:357. doi: 10.1186/s13063-021-05266-w

Table 1.

Summary statistics for patient characteristics in the CRASH-2 trial

Patient level characteristics Tranexamic acid (n = 10,060) Placebo (n = 10,067)
Age (years)
 Mean (SD) 34.6 (14.14) 34.5 (14.39)
 < 25 2777 (27.6%) 2838 (28.2%)
 25–34 3006 (29.9%) 3070 (30.5%)
 35–44 1966 (19.5%) 1832 (18.2%)
 > 44 2311 (23.0%) 2326 (23.1%)
Sex
 Men 8413 (83.6%) 8456 (84.0%)
 Women 1647 (16.4%) 1610 (15.99%)
 Not known 0 1 (0.01%)
Glasgow Coma Scale (total)
 Severe (3–8) 1789 (17.8%) 1830 (18.2%)
 Moderate (9–12) 1349 (13.4%) 1344 (13.4%)
 Mild (13–15) 6915 (68.7%) 6877 (68.3%)
 Not known 7 (< 1%) 16 (< 1%)
Time since injury (hours)
 Mean (SD) 3.22 (19.99) 3.26 (20.03)
 ≤ 1 3747 (37.3%) 3705 (36.8%)
 > 1–3 3037 (30.2%) 2996 (29.8%)
 > 3 3272 (32.5%) 3362 (33.4%)
 Not known 4 (0.04%) 4 (0.04%)
Type of injury
 Blunt* 6788 (67.5%) 6817 (67.7%)
 Penetrating 3272 (32.5%) 3250 (32.3%)
Systolic blood pressure (mm Hg)
 ≤ 75 1562 (15.5%) 1599 (15.9%)
 76–89 1609 (16.0%) 1689 (16.8%)
 ≥ 90 6878 (68.4%) 6761 (67.2%)
 Not known 11 (< 1%) 18 (< 1%)
28-day mortality
 Dead (all-cause) 1463 (14.5%) 1613 (16.0%)
 Dead due to bleeding 489 (4.9%) 575 (5.7%)

*Includes patients with both blunt and penetrating and those with only blunt injuries